Kwok Brian, Hall Jeff M, Witte John S, Xu Yin, Reddy Prashanti, Lin Keming, Flamholz Rachel, Dabbas Bashar, Yung Aine, Al-Hafidh Jenan, Balmert Emily, Vaupel Christine, El Hader Carlos, McGinniss Matthew J, Nahas Shareef A, Kines Julie, Bejar Rafael
Genoptix Medical Laboratory, Carlsbad, CA;
Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA; and.
Blood. 2015 Nov 19;126(21):2355-61. doi: 10.1182/blood-2015-08-667063. Epub 2015 Oct 1.
Establishing a diagnosis in patients suspected of having a myelodysplastic syndrome (MDS) can be challenging and could be informed by the identification of somatic mutations. We performed a prospective study to examine the frequency and types of mutations encountered in 144 patients with unexplained cytopenias. Based on bone marrow findings, 17% were diagnosed with MDS, 15% with idiopathic cytopenias of undetermined significance (ICUS) and some evidence of dysplasia, and 69% with ICUS and no dysplasia. Bone marrow DNA was sequenced for mutations in 22 frequently mutated myeloid malignancy genes. Somatic mutations were identified in 71% of MDS patients, 62% of patients with ICUS and some dysplasia, and 20% of ICUS patients and no dysplasia. In total, 35% of ICUS patients carried a somatic mutation or chromosomal abnormality indicative of clonal hematopoiesis. We validated these results in a cohort of 91 lower-risk MDS and 249 ICUS cases identified over a 6-month interval. Mutations were found in 79% of those with MDS, in 45% of those with ICUS with dysplasia, and in 17% of those with ICUS without dysplasia. The spectrum of mutated genes was similar with the exception of SF3B1 which was rarely mutated in patients without dysplasia. Variant allele fractions were comparable between clonal ICUS (CCUS) and MDS as were mean age and blood counts. We demonstrate that CCUS is a more frequent diagnosis than MDS in cytopenic patients. Clinical and mutational features are similar in these groups and may have diagnostic utility once outcomes in CCUS patients are better understood.
对疑似患有骨髓增生异常综合征(MDS)的患者进行诊断可能具有挑战性,而体细胞突变的鉴定可为诊断提供依据。我们进行了一项前瞻性研究,以检查144例不明原因血细胞减少患者中所遇到的突变频率和类型。根据骨髓检查结果,17%的患者被诊断为MDS,15%为意义未明的特发性血细胞减少症(ICUS)且有一些发育异常的证据,69%为ICUS且无发育异常。对骨髓DNA进行测序,以检测22个常见突变的髓系恶性肿瘤基因中的突变。在MDS患者中,71%检测到体细胞突变;在有一些发育异常的ICUS患者中,62%检测到体细胞突变;在无发育异常的ICUS患者中,20%检测到体细胞突变。总体而言,35%的ICUS患者携带指示克隆性造血的体细胞突变或染色体异常。我们在一个由91例低危MDS和249例ICUS病例组成的队列中验证了这些结果,这些病例是在6个月的时间间隔内确定的。在MDS患者中,79%发现有突变;在有发育异常的ICUS患者中,45%发现有突变;在无发育异常的ICUS患者中,17%发现有突变。除了SF3B1在无发育异常的患者中很少发生突变外,突变基因谱相似。克隆性ICUS(CCUS)和MDS之间的变异等位基因分数相当,平均年龄和血细胞计数也相当。我们证明,在血细胞减少患者中,CCUS的诊断比MDS更常见。这些组中的临床和突变特征相似,一旦对CCUS患者的结局有了更好的了解,可能具有诊断价值。